Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

The Natural Course of Biopsy-Proven Isolated Microscopic Hematuria: a Single Center Experience of 350 Patients.

Lee HM, Hyun JI, Min JW, Lee K, Kim YK, Choi EJ, Song HC.

J Korean Med Sci. 2016 Jun;31(6):909-14. doi: 10.3346/jkms.2016.31.6.909. Epub 2016 Apr 18.

2.

Haematuria on the Spanish Registry of Glomerulonephritis.

Yuste C, Rivera F, Moreno JA, López-Gómez JM.

Sci Rep. 2016 Jan 28;6:19732. doi: 10.1038/srep19732.

3.

Dysmorphic erythrocytes are superior to hematuria for indicating non-diabetic renal disease in type 2 diabetics.

Dong ZY, Wang YD, Qiu Q, Hou K, Zhang L, Wu J, Zhu HY, Cai GY, Sun XF, Zhang XG, Liu MY, Kou J, Chen XM.

J Diabetes Investig. 2016 Jan;7(1):115-20. doi: 10.1111/jdi.12371. Epub 2015 Jun 11.

4.

Heavy hematuria requiring cystectomy in a patient with hemophilia A: a case report and literature review.

Washino S, Hirai M, Kobayashi Y, Saito K, Miyagawa T.

BMC Urol. 2015 Aug 13;15:84. doi: 10.1186/s12894-015-0076-8. Review.

5.

Comparison of frequency of asymptomatic microhematuria in patients with stage 2-4 versus stage 0-1 pelvic organ prolapse.

Töz E, Kurt S, Canda MT, Şahin Ç, Uyar I.

Pak J Med Sci. 2015;31(3):654-7. doi: 10.12669/pjms.313.6934.

6.

Pathogenesis of glomerular haematuria.

Yuste C, Gutierrez E, Sevillano AM, Rubio-Navarro A, Amaro-Villalobos JM, Ortiz A, Egido J, Praga M, Moreno JA.

World J Nephrol. 2015 May 6;4(2):185-95. doi: 10.5527/wjn.v4.i2.185. Review.

7.

Non-visible versus visible haematuria and bladder cancer risk: a study of electronic records in primary care.

Price SJ, Shephard EA, Stapley SA, Barraclough K, Hamilton WT.

Br J Gen Pract. 2014 Sep;64(626):e584-9. doi: 10.3399/bjgp14X681409.

8.

Haematuria: an imaging guide.

Moloney F, Murphy KP, Twomey M, O'Connor OJ, Maher MM.

Adv Urol. 2014;2014:414125. doi: 10.1155/2014/414125. Epub 2014 Jul 17. Review.

9.

Association between arsenic exposure from drinking water and hematuria: results from the Health Effects of Arsenic Longitudinal Study.

McClintock TR, Chen Y, Parvez F, Makarov DV, Ge W, Islam T, Ahmed A, Rakibuz-Zaman M, Hasan R, Sarwar G, Slavkovich V, Bjurlin MA, Graziano JH, Ahsan H.

Toxicol Appl Pharmacol. 2014 Apr 1;276(1):21-7. doi: 10.1016/j.taap.2014.01.015. Epub 2014 Jan 28.

10.

The use of molecular analyses in voided urine for the assessment of patients with hematuria.

Beukers W, Kandimalla R, van Houwelingen D, Kovacic H, Chin JF, Lingsma HF, Dyrskjot L, Zwarthoff EC.

PLoS One. 2013 Oct 15;8(10):e77657. doi: 10.1371/journal.pone.0077657. eCollection 2013.

11.

Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.

Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, Mian C, Martini T, Pycha A, Shariat SF, Schmitz-Dräger BJ.

World J Urol. 2012 Dec;30(6):847-52. doi: 10.1007/s00345-012-0979-x. Epub 2012 Nov 5.

12.

A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria.

Karnes RJ, Fernandez CA, Shuber AP.

Mayo Clin Proc. 2012 Sep;87(9):835-42. doi: 10.1016/j.mayocp.2012.04.013. Epub 2012 Aug 9.

13.

Macroscopic hematuria-a leading urological problem in patients on anticoagulant therapy: is the common diagnostic standard still advisable?

Antoniewicz AA, Zapała L, Poletajew S, Borówka A.

ISRN Urol. 2012;2012:710734. doi: 10.5402/2012/710734. Epub 2012 Apr 1.

14.

A miR-1207-5p binding site polymorphism abolishes regulation of HBEGF and is associated with disease severity in CFHR5 nephropathy.

Papagregoriou G, Erguler K, Dweep H, Voskarides K, Koupepidou P, Athanasiou Y, Pierides A, Gretz N, Felekkis KN, Deltas C.

PLoS One. 2012;7(2):e31021. doi: 10.1371/journal.pone.0031021. Epub 2012 Feb 2.

15.

The predictive value of cancer symptoms in primary care.

Barraclough K.

Br J Gen Pract. 2010 Sep;60(578):639-40. doi: 10.3399/bjgp10X515304. No abstract available.

16.

Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.

Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC.

Lancet. 2010 Sep 4;376(9743):794-801. doi: 10.1016/S0140-6736(10)60670-8. Epub 2010 Aug 25.

17.

High-risk patients with hematuria are not evaluated according to guideline recommendations.

Elias K, Svatek RS, Gupta S, Ho R, Lotan Y.

Cancer. 2010 Jun 15;116(12):2954-9. doi: 10.1002/cncr.25048.

18.

Urine-based assays for the detection of bladder cancer.

Villicana P, Whiting B, Goodison S, Rosser CJ.

Biomark Med. 2009 Jun 1;3(3):265.

19.

Renal biopsy in patients with type 2 diabetes mellitus: indications and nature of the lesions.

Ghani AA, Al Waheeb S, Al Sahow A, Hussain N.

Ann Saudi Med. 2009 Nov-Dec;29(6):450-3. doi: 10.4103/0256-4947.57167.

20.

Bladder tumor in women with microscopic hematuria: an Iranian experience and a review of the literature.

Abbaszadeh S, Taheri S, Nourbala MH.

Adv Urol. 2009:231861. doi: 10.1155/2009/231861. Epub 2009 Jul 20.

Items per page

Supplemental Content

Write to the Help Desk